BioArctic announces that exidavnemab demonstrated good safety and tolerability in the first cohort of the Phase IIa EXIST trial for Parkinson's disease. Following positive safety evaluation, two additional cohorts with higher doses are now being initiated for both Parkinson's disease and multiple system atrophy (MSA). The study is evaluating safety, pharmacokinetics and biomarkers for slowing disease progression by targeting aggregated alpha-synuclein.
BioArctic advances phase IIa study with exidavnemab
Notes
iZafe takes the next step in the Nordics – begins Finnish partnership for Dosell
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
NEWSLETTER
NEWS
Merck gears up in lung diseases with giant acquisition
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AlzeCure Pharma: “We have good momentum”
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
